Circulation, Vol 90, 61-68, Copyright © 1994 by American Heart Association
PA Merlini, KA Bauer, L Oltrona, D Ardissino, M Cattaneo, C Belli, PM Mannucci and RD Rosenberg
BACKGROUND: The blood coagulation system is activated in the acute phase of
unstable angina and acute myocardial infarction. However, it remains
unclear whether augmented function of the hemostatic mechanism serves only
as a marker of the acute thrombotic episode or whether a hypercoagulable
state persists for a prolonged period after clinical stabilization. METHODS
AND RESULTS: We prospectively measured the plasma concentrations of
prothrombin fragment 1 + 2 (F1 + 2) and fibrinopeptide A (FPA) in
consecutive patients presenting with unstable angina (n = 81) or acute
myocardial infarction (n = 32), respectively. At 6 months, plasma
determinations were repeated in patients experiencing an uneventful
clinical course (unstable angina, n = 57; myocardial infarction, n = 23).
We quantitated the plasma levels of F1 + 2 and FPA in control patients with
stable angina (n = 37) or healthy individuals (n = 32) who were matched for
age and sex. The median plasma concentrations of F1 + 2 and FPA are
significantly higher in patients presenting with unstable angina (F1 + 2,
1.08 nmol/L; FPA, 2.4 nmol/L) or acute myocardial infarction (F1 + 2, 1.27
nmol/L; FPA, 3.55 nmol/L) compared with patients with stable angina (F1 +
2, 0.74 nmol/L; FPA, 1.3 nmol/L; P < .0001) or healthy individuals (F1 +
2, 0.71 nmol/L; FPA, 0.80 nmol/L; P < .0001). At 6 months, the median
plasma levels of F1 + 2 in patients exhibiting an uneventful clinical
course did not differ from values obtained at admission (unstable angina,
1.26 versus 1.07 nmol/L, P = NS; myocardial infarction, 1.22 versus 1.29
nmol/L, P = NS), whereas the median plasma levels of FPA in the same two
subpopulations were significantly reduced (unstable angina, 1.1 versus 2.9
nmol/L, P = .0003; myocardial infarction, 1.1 versus 3.0 nmol/L; P =
.0028). CONCLUSIONS: During the acute phase of unstable angina and
myocardial infarction, patients exhibit increased coagulation system
activity. Over the next 6 months, patients with unstable angina or
myocardial infarction experiencing an uneventful clinical course manifest a
persistent hypercoagulable state with minimal generation of fibrin.
ARTICLES
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
2nd Division of Cardiology, Ca'Granda Niguarda Hospital, Milan, Italy.
This article has been cited by other articles:
![]() |
T. P. Greco, A. M. Conti-Kelly, T. Greco Jr, R. Doyle, E. Matsuura, J. R. Anthony, and L. R. Lopez Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome Am J Clin Pathol, October 1, 2009; 132(4): 613 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Palmerini, A. Marzocchi, C. Tamburino, I. Sheiban, M. Margheri, G. Vecchi, G. Sangiorgi, A. Santarelli, A. L. Bartorelli, C. Briguori, et al. Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol., April 7, 2009; 53(14): 1176 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann Systemic blood coagulation activation in acute coronary syndromes Blood, February 26, 2009; 113(9): 2070 - 2078. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Shishehbor, S. Madhwal, V. Rajagopal, A. Hsu, P. Kelly, H. S. Gurm, S. R. Kapadia, M. S. Lauer, and E. J. Topol Impact of Blood Transfusion on Short- and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 46 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Van De Graaff, M. Dutta, P. Das, E. A. Shry, P. D. Frederick, M. Blaney, D. J. Pasta, and S. R. Steinhubl Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke With Acute Myocardial Infarction Stroke, October 1, 2006; 37(10): 2546 - 2551. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pleym, V. Videm, A. Wahba, A. Asberg, T. Amundsen, L. Bjella, O. Dale, and R. Stenseth Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 933 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone and H. D. Aronow Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy Mayo Clin. Proc., May 1, 2006; 81(5): 641 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, Y. Huo, M.-C. Toufektsian, S. I. Ramos, Y. Ma, A. D. Tejani, B. A. French, and Z. Yang Activated platelets contribute importantly to myocardial reperfusion injury Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H692 - H699. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bartnik, K. Malmberg, and L. Ryden Management of patients with type 2 diabetes after acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 144 - 154. [Abstract] [PDF] |
||||
![]() |
M. B. Rothberg, C. Celestin, L. D. Fiore, E. Lawler, and J. R. Cook Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit Ann Intern Med, August 16, 2005; 143(4): 241 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Furie, R. Rosenberg, J. L. Thompson, K. Bauer, J. P. Mohr, B. Rosner, R. Sciacca, S. Barzegar, B. Thornell, T. Costigan, et al. Thrombin generation in non-cardioembolic stroke subtypes: The Hemostatic System Activation Study Neurology, September 14, 2004; 63(5): 777 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Butenas, T. Orfeo, M. T. Gissel, K. E. Brummel, and K. G. Mann The Significance of Circulating Factor IXa in Blood J. Biol. Chem., May 28, 2004; 279(22): 22875 - 22882. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird Thrombin and Phenotypic Modulation of the Endothelium Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 41 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Golino, A. Ravera, M. Ragni, P. Cirillo, O. Piro, and M. Chiariello Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes Circulation, December 9, 2003; 108(23): 2864 - 2869. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rak and J. I. Weitz Heparin and Angiogenesis: Size Matters! Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 1954 - 1955. [Full Text] [PDF] |
||||
![]() |
D. Ardissino, P. A. Merlini, K. A. Bauer, M. Galvani, F. Ottani, F. Franchi, F. Bertocchi, R. D. Rosenberg, and P. M. Mannucci Coagulation activation and long-term outcome in acute coronary syndromes Blood, October 15, 2003; 102(8): 2731 - 2735. [Abstract] [Full Text] [PDF] |
||||
![]() |
I P Casserly and E J Topol The primacy of clinical effectiveness for cost effectiveness analysis Heart, March 1, 2003; 89(3): 249 - 250. [Full Text] [PDF] |
||||
![]() |
M Janzon, L-A Levin, and E Swahn Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial Heart, March 1, 2003; 89(3): 287 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Mehta and S. Yusuf Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 79S - 88S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hauptmann, A. K. Mohan, M. M. Doody, M. S. Linet, and K. Mabuchi Mortality from Diseases of the Circulatory System in Radiologic Technologists in the United States Am. J. Epidemiol., February 1, 2003; 157(3): 239 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
P J Sheridan and D C Crossman Critical review of unstable angina and non-ST elevation myocardial infarction Postgrad. Med. J., December 1, 2002; 78(926): 717 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.W. Eikelboom, J.I. Weitz, A. Budaj, F. Zhao, I. Copland, P. Maciejewski, M. Johnston, and S. Yusuf Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes Eur. Heart J., November 2, 2002; 23(22): 1771 - 1779. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kottke-Marchant, M.C. Bahit, C.B. Granger, P. Zoldhelyi, D. Ardissino, L. Brooks, J.H. Griffin, R.F. Potthoff, F. Van de Werf, R.M. Califf, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes Eur. Heart J., August 1, 2002; 23(15): 1202 - 1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.E. Husted, L. Wallentin, B. Lagerqvist, F. Kontny, E. Stahle, and E. Swahn Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization Eur. Heart J., August 1, 2002; 23(15): 1213 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ageno and A. G.G. Turpie New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins Can. Med. Assoc. J., April 1, 2002; 166(7): 919 - 924. [Full Text] [PDF] |
||||
![]() |
M. A. Brouwer and F. W.A. Verheugt Oral Anticoagulation for Acute Coronary Syndromes Circulation, March 19, 2002; 105(11): 1270 - 1274. [Full Text] [PDF] |
||||
![]() |
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Weitz and H. R. Buller Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future Circulation, February 26, 2002; 105(8): 1004 - 1011. [Full Text] [PDF] |
||||
![]() |
M. Labinaz, R. Kilaru, K. Pieper, S. P. Marso, M. M. Kitt, M. L. Simoons, R. M. Califf, E. J. Topol, P. W. Armstrong, and R. A. Harrington Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Circulation, January 22, 2002; 105(3): 322 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Savonitto, C. B. Granger, D. Ardissino, L. Gardner, C. Cavallini, M. Galvani, F. Ottani, H. D. White, P. W. Armstrong, E. M. Ohman, et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes J. Am. Coll. Cardiol., January 2, 2002; 39(1): 22 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Lockowandt and A. Franco-Cereceda Off-pump coronary bypass surgery causes less immediate postoperative coronary endothelial dysfunction compared to on-pump coronary bypass surgery Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1147 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hasumura, N. Aoki, K. Kawano, M. Homori, A. Maki, Y. Hioki, K. Ishikawa, and H. Yoshino Platelet-Dependent Thrombin Generation in Patients with Unstable Angina Pectoris Angiology, December 1, 2001; 52(12): 811 - 818. [Abstract] [PDF] |
||||
![]() |
T. Tokunou, T. Ichiki, K. Takeda, Y. Funakoshi, N. Iino, H. Shimokawa, K. Egashira, and A. Takeshita Thrombin Induces Interleukin-6 Expression Through the cAMP Response Element in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1759 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. G. Turpie and E. M. Antman Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. t. Berg, B. A. Hutten, J. C. Kelder, F. W. A. Verheugt, and H. W. T. Plokker Oral Anticoagulant Therapy During and After Coronary Angioplasty : The Intensity and Duration of Anticoagulation Are Essential to Reduce Thrombotic Complications Circulation, April 24, 2001; 103(16): 2042 - 2047. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. De Lorenzo, A. Noorani, and V.V. Kakkar Current trends in the management of thromboembolic events QJM, April 1, 2001; 94(4): 179 - 185. [Full Text] [PDF] |
||||
![]() |
T. J. Tegos, E. Kalodiki, M. M. Sabetai, and A. N. Nicolaides The Genesis of Atherosclerosis and Risk Factors: A Review Angiology, February 1, 2001; 52(2): 89 - 98. [Abstract] [PDF] |
||||
![]() |
K. M. Akkerhuis, K.-L. Neuhaus, R. G. Wilcox, A. Vahanian, J.-L. Boland, J. Hoffmann, T. Baardman, G. Nehmiz, U. Roth, A. P. J. Klootwijk, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study Eur. Heart J., December 2, 2000; 21(24): 2042 - 2055. [Abstract] [PDF] |
||||
![]() |
J. Figueras, Y. Monasterio, R. M. Lidon, E. Nieto, and J. Soler-Soler Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2036 - 2043. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ageno and A. G. Turpie Therapy of unstable angina with the low molecular weight heparins Vascular Medicine, November 1, 2000; 5(4): 217 - 223. [Abstract] [PDF] |
||||
![]() |
A. Sonel, B. M. Sasseen, N. Fineberg, N. Bang, and R. L. Wilensky Prospective Study Correlating Fibrinopeptide A, Troponin I, Myoglobin, and Myosin Light Chain Levels With Early and Late Ischemic Events in Consecutive Patients Presenting to the Emergency Department With Chest Pain Circulation, September 5, 2000; 102(10): 1107 - 1113. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Goodman, M. Cohen, F. Bigonzi, E. P. Gurfinkel, D. R. Radley, V. Le Iouer, G. J. Fromell, C. Demers, A. G. G. Turpie, R. M. Califf, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence study J. Am. Coll. Cardiol., September 1, 2000; 36(3): 693 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432. [PDF] |
||||
![]() |
P. A. Merlini, D. Ardissino, R. D. Rosenberg, E. Colombi, P. Agricola, L. Oltrona, F. Ottani, M. Galvani, K. A. Bauer, B. Bottasso, et al. In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2162 - 2166. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Cote, C. Wolfson, S. Solymoss, A. Mackey, J. R Leclerc, D. Simard, F. Rouah, F. Bourque, and B. Leger Hemostatic Markers in Patients at Risk of Cerebral Ischemia Stroke, August 1, 2000; 31(8): 1856 - 1862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Coulter, C. P. Cannon, K. A. Ault, E. M. Antman, F. Van de Werf, A. A. J. Adgey, C. M. Gibson, R. P. Giugliano, M. A. Mascelli, J. Scherer, et al. High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14 Circulation, June 13, 2000; 101(23): 2690 - 2695. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Kirklin Pediatric cardiac transplantation Ann. Thorac. Surg., May 1, 2000; 69(5): 1627 - 1628. [Full Text] [PDF] |
||||
![]() |
H. J. Teede, B. P. McGrath, J. J. Smolich, E. Malan, D. Kotsopoulos, Y.-L. Liang, and R. E. Peverill Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1404 - 1409. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Feng, G. H. Tofler, M. G. Larson, C. J. O’Donnell, I. Lipinska, C. Schmitz, P. A. Sutherland, M. T. Johnstone, J. E. Muller, R. B. D’Agostino, et al. Factor VII Gene Polymorphism, Factor VII Levels, and Prevalent Cardiovascular Disease : The Framingham Heart Study Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 593 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Anand and S. Yusuf Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis JAMA, December 1, 1999; 282(21): 2058 - 2067. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Antman, C. H. McCabe, E. P. Gurfinkel, A. G. G. Turpie, P. J. L. M. Bernink, D. Salein, A. Bayes de Luna, K. Fox, J.-M. Lablanche, D. Radley, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction : Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial Circulation, October 12, 1999; 100(15): 1593 - 1601. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Becker, F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1020 - 1027. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Moruzzi, S Sarzi-Braga, M Rossi, and M Contini Sleep apnoea in ischaemic heart disease: differences between acute and chronic coronary syndromes Heart, September 1, 1999; 82(3): 343 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Soejima, H. Ogawa, H. Yasue, K. Kaikita, K. Nishiyama, K. Misumi, K. Takazoe, Y. Miyao, M. Yoshimura, K. Kugiyama, et al. Heightened Tissue Factor Associated With Tissue Factor Pathway Inhibitor and Prognosis in Patients With Unstable Angina Circulation, June 8, 1999; 99(22): 2908 - 2913. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Li, J.-K. Teng, W.-C. Tsai, L.-M. Tsai, L.-J. Lin, H.-R. Guo, and J.-H. Chen Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1543 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Vorchheimer, J. J. Badimon, and V. Fuster Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease JAMA, April 21, 1999; 281(15): 1407 - 1414. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. H. M. Verheggen, M. P. M. de Maat, V. M. Cats, F. Haverkate, A. H. Zwinderman, C. Kluft, and A. V. G. Bruschke Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function Eur. Heart J., April 2, 1999; 20(8): 567 - 574. [Abstract] [PDF] |
||||
![]() |
R. Linder, J. Oldgren, N. Egberg, L. Grip, G. Larson, A. Siegbahn, and L. Wallentin The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease Eur. Heart J., April 1, 1999; 20(7): 506 - 518. [Abstract] [PDF] |
||||
![]() |
M. Pahor, M. B. Elam, R. J. Garrison, S. B. Kritchevsky, and W. B. Applegate Emerging Noninvasive Biochemical Measures to Predict Cardiovascular Risk Arch Intern Med, February 8, 1999; 159(3): 237 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Braunwald Unstable Angina : An Etiologic Approach to Management Circulation, November 24, 1998; 98(21): 2219 - 2222. [Full Text] [PDF] |
||||
![]() |
D. A. Halon, M. Y. Flugelman, A. Merdler, H. Rennert, J. Shahla, and B. S. Lewis Long-term (10-year) outcome in patients with unstable angina pectoris treated by coronary balloon angioplasty J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1603 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Manten, R. J. de Winter, M. C. Minnema, H. ten Cate, J. G. Lijmer, R. Adams, R. J.G. Peters, and S. J.H. van Deventer Procoagulant and proinflammatory activity in acute coronary syndromes Cardiovasc Res, November 1, 1998; 40(2): 389 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Anand, S. Yusuf, J. Pogue, J. I. Weitz, and M. Flather Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non–Q-Wave Myocardial Infarction : Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study Results Circulation, September 15, 1998; 98(11): 1064 - 1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Antman and R. Handin Low-Molecular-Weight Heparins : An Intriguing New Twist With Profound Implications Circulation, July 28, 1998; 98(4): 287 - 289. [Full Text] [PDF] |
||||
![]() |
N P Curzen, D J Patel, M Kemp, J Hooper, C J Knight, D Clarke, C Wright, and K M Fox Can C reactive protein or troponins T and I predict outcome in patients with intractable unstable angina? Heart, July 1, 1998; 80(1): 23 - 27. [Abstract] [Full Text] |
||||
![]() |
J. H. Chesebro and J. J. Badimon Platelet Glycoprotein IIb/IIIa Receptor Blockade in Unstable Coronary Disease N. Engl. J. Med., May 21, 1998; 338(21): 1538 - 1541. [Full Text] |
||||
![]() |
W. T. Hermens, M. M. A. L. Pelsers, M.-L. Mullers-Boumans, C. de Zwaan, and J. F. C. Glatz Combined Use of Markers of Muscle Necrosis and Fibrinogen Conversion in the Early Differentiation of Myocardial Infarction and Unstable Angina Clin. Chem., April 1, 1998; 44(4): 890 - 892. [Full Text] [PDF] |
||||
![]() |
D. A. Vorchheimer and V. Fuster Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonists: The Present Challenge Is Safety Circulation, February 3, 1998; 97(4): 312 - 314. [Full Text] [PDF] |
||||
![]() |
G. Ghigliotti, A. R. Waissbluth, C. Speidel, D. R. Abendschein, and P. R. Eisenberg Prolonged Activation of Prothrombin on the Vascular Wall After Arterial Injury Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 250 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bernardi, P. Arcieri, R. M. Bertina, F. Chiarotti, J. Corral, M. Pinotti, H. Prydz, M. Samama, P. M. Sandset, R. Strom, et al. Contribution of Factor VII Genotype to Activated FVII Levels : Differences in Genotype Frequencies Between Northern and Southern European Populations Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2548 - 2553. [Abstract] [Full Text] |
||||
![]() |
M. Frohlich, M. Sund, S. Russ, A. Hoffmeister, H. G. Fischer, V. Hombach, and W. Koenig Seasonal Variations of Rheological and Hemostatic Parameters and Acute-Phase Reactants in Young, Healthy Subjects Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2692 - 2697. [Abstract] [Full Text] |
||||
![]() |
F.-C. Schoebel, F. Gradaus, K. Ivens, P. Heering, T. W. Jax, B. Grabensee, B.-E. Strauer, and M. Leschke Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography Heart, October 1, 1997; 78(4): 337 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Merlini, D. Ardissino, K. A. Bauer, L. Oltrona, A. Pezzano, B. Bottasso, R. D. Rosenberg, and P. M. Mannucci Persistent Thrombin Generation During Heparin Therapy in Patients With Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, July 1, 1997; 17(7): 1325 - 1330. [Abstract] [Full Text] |
||||
![]() |
W. Klein, A. Buchwald, S. E. Hillis, S. Monrad, G. Sanz, A. G. G. Turpie, J. van der Meer, E. Olaisson, S. Undeland, and K. Ludwig Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease : Fragmin in Unstable Coronary Artery Disease Study (FRIC) Circulation, July 1, 1997; 96(1): 61 - 68. [Abstract] [Full Text] |
||||
![]() |
W. M. Feinberg, E. S. Cornell, S. D. Nightingale, L. A. Pearce, R. P. Tracy, R. G. Hart, and E. G. Bovill Relationship Between Prothrombin Activation Fragment F1.2 and International Normalized Ratio in Patients With Atrial Fibrillation Stroke, June 1, 1997; 28(6): 1101 - 1106. [Abstract] [Full Text] |
||||
![]() |
L. Oltrona, M. Broccolino, P. A. Merlini, A. Spinola, A. Pezzano, and P. M. Mannucci Activation of the Hemostatic Mechanism After Pharmacological Cardioversion of Acute Nonvalvular Atrial Fibrillation Circulation, April 15, 1997; 95(8): 2003 - 2006. [Abstract] [Full Text] |
||||
![]() |
H. Philippou, A. Adami, R. A. Amersey, P. J. Stubbs, and D. A. Lane A Novel Specific Immunoassay for Plasma Two-Chain Factor VIIa: Investigation of FVIIa Levels in Normal Individuals and in Patients With Acute Coronary Syndromes Blood, February 1, 1997; 89(3): 767 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Rao, L. Sun, J. H. Chesebro, V. Fuster, R. A. Harrington, D. Schwartz, P. Gallo, D. Matos, and E. J. Topol Distinct Effects of Recombinant Desulfatohirudin (Revasc) and Heparin on Plasma Levels of Fibrinopeptide A and Prothrombin Fragment F1.2 in Unstable Angina: A Multicenter Trial Circulation, November 15, 1996; 94(10): 2389 - 2395. [Abstract] [Full Text] |
||||
![]() |
L. Oltrona, P. R. Eisenberg, J. M. Lasala, D. J. Sewall, M. E. Shelton, and K. J. Winters Association of Heparin-Resistant Thrombin Activity With Acute Ischemic Complications of Coronary Interventions Circulation, November 1, 1996; 94(9): 2064 - 2071. [Abstract] [Full Text] |
||||
![]() |
C. R. McKenzie, D. R. Abendschein, and P. R. Eisenberg Sustained Inhibition of Whole-Blood Clot Procoagulant Activity by Inhibition of Thrombus-Associated Factor Xa Arterioscler Thromb Vasc Biol, October 1, 1996; 16(10): 1285 - 1291. [Abstract] [Full Text] |
||||
![]() |
J. D. Marmur, S. V. Thiruvikraman, B. S. Fyfe, A. Guha, S. K. Sharma, J. A. Ambrose, J. T. Fallon, Y. Nemerson, and M. B. Taubman Identification of Active Tissue Factor in Human Coronary Atheroma Circulation, September 15, 1996; 94(6): 1226 - 1232. [Abstract] [Full Text] |
||||
![]() |
J. A. Ambrose and M. Weinrauch Thrombosis in Ischemic Heart Disease Arch Intern Med, July 8, 1996; 156(13): 1382 - 1394. [Abstract] [PDF] |
||||
![]() |
L. M. Biasucci, G. Liuzzo, G. Caligiuri, G. Quaranta, F. Andreotti, G. Sperti, W. van de Greef, A. G. Rebuzzi, C. Kluft, and A. Maseri Temporal Relation Between Ischemic Episodes and Activation of the Coagulation System in Unstable Angina Circulation, June 15, 1996; 93(12): 2121 - 2127. [Abstract] [Full Text] |
||||
![]() |
D. Ardissino, P. A. Merlini, G. Gamba, P. Barberis, G. Demicheli, S. Testa, E. Colombi, A. Poli, R. Fetiveau, and C. Montemartini Thrombin Activity and Early Outcome in Unstable Angina Pectoris Circulation, May 1, 1996; 93(9): 1634 - 1639. [Abstract] [Full Text] |
||||
![]() |
P. A. Merlini, D. Ardissino, L. Oltrona, M. Broccolino, R. Coppola, and P. M. Mannucci Heightened Thrombin Formation but Normal Plasma Levels of Activated Factor VII in Patients With Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, October 1, 1995; 15(10): 1675 - 1679. [Abstract] [Full Text] |
||||
![]() |
T. Murakami, Y. Komiyama, M. Masuda, M. Karakawa, T. Iwasaka, and H. Takahashi Evaluation of Factor XIa–{alpha}1-Antitrypsin in Plasma, a Contact Phase–Activated Coagulation Factor–Inhibitor Complex, in Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, August 1, 1995; 15(8): 1107 - 1113. [Abstract] [Full Text] |
||||
![]() |
E. Falk, P. K. Shah, and V. Fuster Coronary Plaque Disruption Circulation, August 1, 1995; 92(3): 657 - 671. [Full Text] |
||||
![]() |
D. Pratico and G. A. FitzGerald Testosterone and Thromboxane : Of Muscles, Mice, and Men Circulation, June 1, 1995; 91(11): 2694 - 2698. [Full Text] |
||||
![]() |
P. A. Merlini, A. Repetto, A. Lombardi, A. Vetrano, R. Fetiveau, C. Cavallini, D. Sappe, A. Salvioni, R. Canziani, S. Savonitto, et al. Effect of Abciximab on Prothrombin Activation and Thrombin Generation in Acute Coronary Syndromes Without ST-Segment Elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy Circulation, February 26, 2002; 105(8): 928 - 932. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1994 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |